HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Clinical trial of bestrabucil (KM 2210) in hematopoietic malignancies].

Abstract
Thirteen patients with hematological neoplasms were treated with Bestrabucil (100 mg/day po, total dose 700-9,900 mg), which is the benzoate of an estradiol-chlorambucil conjugate. The diseases from which they suffered consisted of T-cell leukemia (3), lymphoma (3), myeloma (5) and essential thrombocytosis (2). Although this drug was less effective against myeloma, the other diseases were more or less relieved with this medication. That is, Bestrabucil was effective in all three patients with T-cell leukemia, both with essential thrombocytosis and two of the three with lymphoma. It is most interesting that adult T-cell leukemia (ATL) cells decreased remarkably with Bestrabucil, along with the disappearance of several symptoms (bone pain, hypercalcemia etc.). The main side effects during this medication were mammary pain (eight of 13 patients, 62%), anorexia (five of 13 patients, 39%) and loss of libido (three of 13 patients, 23%), but neither severe myelosuppression nor hepatorenal dysfunction was induced.
AuthorsK Naito, K Kubo, Y Akao, A Hiraiwa, T Naoe, K Yamada
JournalGan no rinsho. Japan journal of cancer clinics (Gan No Rinsho) Vol. 32 Issue 11 Pg. 1443-50 (Sep 1986) ISSN: 0021-4949 [Print] Japan
PMID2877106 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Chlorambucil
  • Estradiol
  • bestrabucil
Topics
  • Aged
  • Chlorambucil (analogs & derivatives, therapeutic use)
  • Deltaretrovirus Infections (drug therapy)
  • Estradiol (analogs & derivatives, therapeutic use)
  • Female
  • Humans
  • Lymphoma (drug therapy)
  • Male
  • Middle Aged
  • Multiple Myeloma (drug therapy)
  • Thrombocytosis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: